Abeona Therapeutics Inc. (ABEO) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Abiona Therapeutics (ABEO) Q1 2026: ZivaSkin Drives $8.7M Launch Revenue as QTC Network Expands to Six
  May 13, 2026
• Abiona Therapeutics (ABEO) Q4 2025: ZivaSkin Patient Pool Doubles, Setting Stage for 7 QTC Ramp
  March 17, 2026
• ABEO Q3 2025: ZivaSkin Patient Pipeline Doubles, Payer Coverage Hits 80% of Commercial Lives
  November 12, 2025
• Abiona Therapeutics (ABEO) Q1 2025: $2B U.S. Revenue Potential Hinges on PZ-Cell Launch Ramp
  July 06, 2025
• Abiona Therapeutics (ABEO) Q3 2024: FDA Sets April PDUFA, Supply to Lag Demand at Launch
  November 14, 2024
• Abiona Therapeutics (ABEO) Q1 2024: $75M Raise Extends Runway Past PZ-Cell FDA Milestones
  May 15, 2024
• ABEO Q4 2023: $52.6M Cash Runway Secures PZ-Cell Launch Readiness Ahead of May FDA Decision
  March 18, 2024
• ABEO Q3 2023: BLA Submission Sets Up $500M Peak Opportunity, Commercial Ramp in Focus
  November 13, 2023

Browse all companies